Works matching IS 01676997 AND DT 2015 AND VI 33 AND IP 4

Results: 25

Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)

Published in:

2015

By:

Chiu, Joanne;
Chan, Kelvin;
Chen, Eric;
Siu, Lillian;
Abdul Razak, Albiruni

Publication type:

Journal Article

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

Published in:

2015

By:

Ma, B.;
Goh, B.;
Lim, W.;
Hui, E.;
Tan, E.;
Lopes, G.;
Lo, K.;
Li, L.;
Loong, H.;
Foster, N.;
Erlichman, C.;
King, A.;
Kam, M.;
Leung, S.;
Chan, K.;
Chan, A.

Publication type:

Journal Article

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 870, doi. 10.1007/s10637-015-0242-6

By:

Garcia-Manero, Guillermo;
Tibes, Raoul;
Kadia, Tapan;
Kantarjian, Hagop;
Arellano, Martha;
Knight, Emily;
Xiong, Hao;
Qin, Qin;
Munasinghe, Wijith;
Roberts-Rapp, Lisa;
Ansell, Peter;
Albert, Daniel;
Oliver, Brian;
McKee, Mark;
Ricker, Justin;
Khoury, Hanna

Publication type:

Article

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 881, doi. 10.1007/s10637-015-0243-5

By:

Horinouchi, Hidehito;
Yamamoto, Noboru;
Fujiwara, Yutaka;
Sekine, Ikuo;
Nokihara, Hiroshi;
Kubota, Kaoru;
Kanda, Shintaro;
Yagishita, Shigehiro;
Wakui, Hiroshi;
Kitazono, Satoru;
Mizugaki, Hidenori;
Tokudome, Takuto;
Tamura, Tomohide

Publication type:

Article

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 890, doi. 10.1007/s10637-015-0244-4

By:

Mitri, Zahi;
Karakas, Cansu;
Wei, Caimiao;
Briones, Brian;
Simmons, Holly;
Ibrahim, Nuhad;
Alvarez, Ricardo;
Murray, James;
Keyomarsi, Khandan;
Moulder, Stacy

Publication type:

Article

Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 895, doi. 10.1007/s10637-015-0245-3

By:

Chiu, Joanne;
Chan, Kelvin;
Chen, Eric;
Siu, Lillian;
Abdul Razak, Albiruni

Publication type:

Article

Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 963, doi. 10.1007/s10637-015-0246-2

By:

Pedersen, Katrina;
Kim, George;
Foster, Nathan;
Wang-Gillam, Andrea;
Erlichman, Charles;
McWilliams, Robert

Publication type:

Article

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 901, doi. 10.1007/s10637-015-0247-1

By:

Ratain, Mark;
Geary, David;
Undevia, Samir;
Coronado, Cinthya;
Alfaro, Vicente;
Iglesias, Jorge;
Schilsky, Richard;
Miguel-Lillo, Bernardo

Publication type:

Article

Generation and tumor recognition properties of two human monoclonal antibodies specific to cell surface anionic phospholipids.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 791, doi. 10.1007/s10637-015-0248-0

By:

Bujak, Emil;
Pretto, Francesca;
Neri, Dario

Publication type:

Article

The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 801, doi. 10.1007/s10637-015-0249-z

By:

Tonissi, Federica;
Lattanzio, Laura;
Merlano, Marco;
Infante, Lucia;
Lo Nigro, Cristiana;
Garrone, Ornella

Publication type:

Article

Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 810, doi. 10.1007/s10637-015-0250-6

By:

Xie, Xinmei;
Wang, Lin;
Yang, Wenliang;
Yu, Ruishuang;
Li, Qingli;
Pang, Xiaobin

Publication type:

Article

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 911, doi. 10.1007/s10637-015-0251-5

By:

Said, Rabih;
Kurzrock, Razelle;
Naing, Aung;
Hong, David;
Fu, Siqing;
Piha-Paul, Sarina;
Wheler, Jennifer;
Janku, Filip;
Kee, Bryan;
Bidyasar, Savita;
Lim, Joann;
Wallace, Michael;
Tsimberidou, Apostolia

Publication type:

Article

A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 969, doi. 10.1007/s10637-015-0252-4

By:

Eigl, B.;
North, S.;
Winquist, E.;
Finch, D.;
Wood, L.;
Sridhar, S.;
Powers, J.;
Good, J.;
Sharma, M.;
Squire, J.;
Bazov, J.;
Jamaspishvili, T.;
Cox, M.;
Bradbury, P.;
Eisenhauer, E.;
Chi, K.

Publication type:

Article

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 942, doi. 10.1007/s10637-015-0258-y

By:

Venkatakrishnan, Karthik;
Kim, Tae;
Lin, Chia-Chi;
Thye, Lim;
Chng, Wee;
Ma, Brigette;
Chen, Ming;
Zhou, Xiaofei;
Liu, Hua;
Kelly, Virginia;
Kim, Won

Publication type:

Article

Amidation inhibitors 4-phenyl-3-butenoic acid and 5-(acetylamino)-4-oxo-6-phenyl-2-hexenoic acid methyl ester are novel HDAC inhibitors with anti-tumorigenic properties.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 827, doi. 10.1007/s10637-015-0254-2

By:

Ali, Amna;
Burns, Timothy;
Lucrezi, Jacob;
May, Sheldon;
Green, George;
Matesic, Diane

Publication type:

Article

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 921, doi. 10.1007/s10637-015-0255-1

By:

Do, Khanh;
Speranza, Giovanna;
Chang, Lun-Ching;
Polley, Eric;
Bishop, Rachel;
Zhu, Weimin;
Trepel, Jane;
Lee, Sunmin;
Lee, Min-Jung;
Kinders, Robert;
Phillips, Larry;
Collins, Jerry;
Lyons, John;
Jeong, Woondong;
Antony, Ramya;
Chen, Alice;
Neckers, Len;
Doroshow, James;
Kummar, Shivaani

Publication type:

Article

Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 931, doi. 10.1007/s10637-015-0256-0

By:

Giri, Nagdeep;
Masters, Joanna;
Plotka, Anna;
Liang, Yali;
Boutros, Tanya;
Pardo, Patricia;
O'Connell, Joseph;
Bello, Carlo

Publication type:

Article

Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 848, doi. 10.1007/s10637-015-0265-z

By:

Collery, Philippe;
Mohsen, Ahmed;
Kermagoret, Anthony;
Corre, Samantha;
Bastian, Gérard;
Tomas, Alain;
Wei, Ming;
Santoni, François;
Guerra, Nadia;
Desmaële, Didier;
d'Angelo, Jean

Publication type:

Article

In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 816, doi. 10.1007/s10637-015-0253-3

By:

Schott, Sarah;
Vallet, Sonia;
Tower, Robert;
Noor, Seema;
Tiwari, Sanjay;
Schem, Christian;
Busch, Christian

Publication type:

Article

Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 835, doi. 10.1007/s10637-015-0260-4

By:

Schreiber-Brynzak, Ekaterina;
Klapproth, Erik;
Unger, Christine;
Lichtscheidl-Schultz, Irene;
Göschl, Simone;
Schweighofer, Sarah;
Trondl, Robert;
Dolznig, Helmut;
Jakupec, Michael;
Keppler, Bernhard

Publication type:

Article

Targeting the plasma membrane of neoplastic cells through alkylation: a novel approach to cancer chemotherapy.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 992, doi. 10.1007/s10637-015-0263-1

By:

Trendowski, Matthew;
Fondy, Thomas

Publication type:

Article

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 985, doi. 10.1007/s10637-015-0264-0

By:

Ma, B.;
Goh, B.;
Lim, W.;
Hui, E.;
Tan, E.;
Lopes, G.;
Lo, K.;
Li, L.;
Loong, H.;
Foster, N.;
Erlichman, C.;
King, A.;
Kam, M.;
Leung, S.;
Chan, K.;
Chan, A.

Publication type:

Article

Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 977, doi. 10.1007/s10637-015-0257-z

By:

Reddy, S.;
Kopetz, S.;
Morris, J.;
Parikh, N.;
Qiao, W.;
Overman, M.;
Fogelman, D.;
Shureiqi, I.;
Jacobs, C.;
Malik, Z.;
Jimenez, C.;
Wolff, R.;
Abbruzzese, J.;
Gallick, G.;
Eng, C.

Publication type:

Article

Cytotoxicity of anthraquinones from the roots of Pentas schimperi towards multi-factorial drug-resistant cancer cells.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 861, doi. 10.1007/s10637-015-0268-9

By:

Kuete, Victor;
Donfack, Arno;
Mbaveng, Armelle;
Zeino, Maen;
Tane, Pierre;
Efferth, Thomas

Publication type:

Article

A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.

Published in:

Investigational New Drugs, 2015, v. 33, n. 4, p. 954, doi. 10.1007/s10637-015-0239-1

By:

Nakayama, Norisuke;
Sato, Atsushi;
Tanaka, Soichi;
Shimada, Ken;
Konishi, Kazuo;
Sasaki, Eisaku;
Hibi, Kenji;
Ichikawa, Hiroko;
Kikuchi, Yoshinori;
Sakuyama, Toshikazu;
Sekikawa, Takashi;
Hayashi, Kazuhiko;
Nishina, Haruhiro

Publication type:

Article